Castle Biosciences (CSTL) Total Liabilities (2018 - 2026)

Castle Biosciences has reported Total Liabilities for 9 years, with the latest figure at $91.1 million in Q2 2026.

• Quarterly Total Liabilities rose 2.01% year-over-year to $91.1 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $91.1 million (up 2.01% YoY) and the FY2025 annual result came in at $107.7 million, up 42.82% from the prior year.
• Total Liabilities improved to $91.1 million in Q2 2026 per CSTL's latest filing, from $86.4 million in the prior quarter.
• Over five years, Total Liabilities peaked at $107.7 million in Q4 2025 and troughed at $36.7 million in Q2 2022.
• A 5-year average of $65.5 million and a median of $61.7 million in 2023 frame the typical range for Total Liabilities.
• The sharpest annual moves came in 2022 and 2023: Total Liabilities surged 151.21% in 2022, then slipped 11.36% in 2023.
• Over 5 years, Total Liabilities stood at $48.2 million in 2022, then gained by 28.83% to $62.1 million in 2023, then gained by 21.47% to $75.4 million in 2024, then surged by 42.82% to $107.7 million in 2025, then decreased by 15.36% to $91.1 million in 2026.
• According to Business Quant data, Total Liabilities over the past three periods registered $91.1 million, $86.4 million, and $107.7 million for Q2 2026, Q1 2026, and Q4 2025 respectively.